Sravani Gundarlapalli

Hematologist Oncologist and Assistant Professor

UAMS

Also affiliated: University of Arkansas Medical Center (2021–2025)

5 h-index 25 pubs 70 cited

Research Areas

Biomedical Subjects

Links

Research Group

OverviewAI-generated summary

Sravani Gundarlapalli's research focuses on the treatment of multiple myeloma, a hematologic malignancy. Her work has investigated various therapeutic strategies, including salvage autologous stem cell transplantation, particularly in patients refractory to treatments like daratumumab. Gundarlapalli has also examined the feasibility and risk factors associated with outpatient stem cell transplantation for multiple myeloma and the role of tandem autologous stem cell transplantation in managing persistent minimal residual disease.

Her publications also address corneal toxicity associated with the immunoconjugate belantamab mafodotin and the clinical efficacy of sequencing CD38-targeting monoclonal antibodies in relapsed refractory multiple myeloma. Gundarlapalli has collaborated with researchers at the University of Arkansas for Medical Sciences, including Nishanth Thalambedu, Jaskirat Sethi, Munawwar Hussain, and Sharmilan Thanendrarajan, on multiple shared publications. Her scholarly output includes 25 publications with 70 citations and an h-index of 5.

Metrics

h-index: 5
Publications: 25
Citations: 70

Positions

Hematologist Oncologist and Assistant Professor publications 2021–2026

University of Arkansas for Medical Sciences Institution web page

Selected Publications

CLL-888: Efficacy and Safety of CAR-T Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
POSTER: CLL-888: Efficacy and Safety of CAR-T Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis (2026)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
In vivo CAR T-cell engineering in B-cell malignancies: A systematic review of emerging clinical and translational evidence. (2026)

Journal of Clinical Oncology DOI OpenAlex
Social vulnerability index as an independent poor prognostic factor in patients with chronic hematological malignancies in Arkansas. (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026)

Transplantation and Cellular Therapy DOI OpenAlex
Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (2022)

Blood DOI OpenAlex
Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant (2022)

Blood DOI OpenAlex
MM-531 Case Control Study of Outcomes of Autologous Stem Cell Transplantation in Jehovah's Witness Multiple Myeloma Patients (2022)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Poster: MM-531 Case Control Study of Outcomes of Autologous Stem Cell Transplantation in Jehovah's Witness Multiple Myeloma Patients (2022)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Corneal toxicity with belantamab mafodotin: Multi‐institutional real‐life experience (2022)

American Journal of Hematology 16 citations DOI OpenAlex
Updates in the Management of Multiple Myeloma from the American Society of Hematology Meeting 2021 (2022)

touchREVIEWS in Oncology & Haematology 1 citation DOI OpenAlex
Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi‐institutional experience (2022)

American Journal of Hematology 6 citations DOI OpenAlex
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission (2022)

Journal of Clinical Medicine 13 citations DOI OpenAlex
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma (2022)

American Journal of Hematology 6 citations DOI OpenAlex
Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance (2021)

Blood 1 citation DOI OpenAlex